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approval to the South African Medicines Control Council
[MCC). Despite discussions between the MCC, investigators,
sponsors and the South African AIDS Vaccine Initiative
(SAAVI), no trial had been approved during this time. After
submission of the first HIV vaccine trial, the MCC mandated
a new committee to deal with HIV vaccine trials, the HIV
Vaccines and Clinical Trials Committee, which has to report
to the MCC meeting before final approval. Initial questions
and responses from the MCC to vaccine trial investigators
have taken between 3 and 18 months. The review by the
HIV Vaccine and Clinical Trials Committee was not only
scientific and regulatory, but also included review of
biomedical ethical issues and the commitment of
researchers to capacity development of previously
disadvantaged communities. The HIV Vaccine and Clinical
Trials Committee wanted assurances of access to lifelong
highly active antiretroviral therapy [HAARn before
approval could be given for the first HIV vaccine trial,
submitted in December 2001. Although the time between
submission and review was lengthy, investigators were
often expected to respond within the standard 7 days of
receipt of the review, often without being able to access
committee members via phone or fax for clarifications. In
the first quarter of 2003, the MCC together with the
National Department of Health convened a meeting with
the National Ethics Committee to gain consensus on
appropriate standard of care for volunteers who become
infected on HIV vaccine trials. There was overwhelming
agreement that access to antiretrovirals was an important
component to the standard of care for trial participants
who became infected on these trials.
The government has not made HAART available in the state
or private sector for the management of HIV-infected
individuals who meet treatment criteria. Because of the
lack of access to HAART in the public sector, there was no
consensus in this country regarding the treatment and
management of participants who may have 'breakthrough'
infections while on vaccine trials. While investigators
subscribe to the UNAlDS ethical considerations in HIV
preventive vaccine research [2()()()) {guidance point 16:
REGULATORY ISSUES
CHALLENGES FACING HIV VACCINE RESEARCH
South Africa is experiencing a severe HIV/AIDS epidemic. It
is estimated that at least 1 in 10 South Africans are HIV-
infected, and data from the 2001 antenatal seroprevalence
survey suggest that at least 1 in 4 pregnant women are
HIV-infected (South African Department of Health). To
date, despite the introduction of national prevention
programmes there is no sound evidence that the epidemic
is reaching a plateau. It has been estimated that HIV
infection rates will peak at almost 17% by 2006 for the
population as a whole. AIDS-related deaths will peak in
2010, at 256 AIDS deaths per 100 non-AIDS-related
deaths.'
Several risk factors in South Africa predispose it to a severe
epidemic. These include a disrupted family and communal
life, due in particular to apartheid and migrant labour;
good transport infrastructure and high mobility; high levels
of poverty and income disparity; evidence of high levels of
sexually transmitted diseases; poor condom use; the low
status of women in society and relationships; and social
norms that accept large numbers of sexual partners. As
mass awareness programmes and prevention strategies
that focus on behaviour change have not curbed the
epidemic, there is an urgent need to investigate biomedical
approaches to HIV prevention. The initiation of an HIV-
vaccine-related research programme in South Africa
presents many challenges to scientists working in this field.
CONDUCTING HIVVACCINE TRIALS
CHAlLENGES FOR SOUTH AFRICA
As yet South Africa has not been involved in HIV vaccine
clinical trials. The challenges facing researchers in South
Africa are not unique, but are barriers similar to those seen
in other developing world settings.
These include:
There is an urgent need to build local regulatory capacity to
review vaccine trials. At present swift in-country review
and the approval process appears to be hampered by
inexperience. Between December 2001 and November
2002, three phase 1/11 trials were submitted for regulatory
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where care and treatment for HIV/AIDS should be provided
to participants in HIV vaccine trials, with the ideal to
provide the best proven therapy, and the minimum to
provide the highest level of care attainable in the host
country), there is lack of clarity regarding who is
responsible for this care.
Attempts to obtain a consensus on the use of antiretroviral
therapy for 'breakthrough' infections held up ethical
clearance of HIV vaccine trials. Since the national meeting
where it was determined that there will be access to
antiretroviral therapy for trial participants who have
'breakthrough' infections while on the trial, the universities
have now given approval for the phase 1/11 HIV vaccine
trials that have been submitted to them.
CROSS-CLADE HIV VACCINE TRIALS
The variability of HIV-l poses a major challenge to the
development of an HIV vaccine. There is controversy among
scientists in this country regarding the value or importance
of cross-clade vaccine research. Trials should be designed
to evaluate whether candidate vaccines are capable of
inducing potent and broad cellular immune responses to
HIV. Because of the increasing diversity of the HIV epidemic
globally, with increasing frequency of recombinant forms,
the development and testing of c1ade-specific vaccines in
regions may not be the appropriate route to take. In South
Africa, approximately 94% of the predominantly
heterosexual epidemic is due to clade C, while 85% of the
minority homosexual epidemic is attributed to c1ade B.'
There are as yet limited data regarding recombinant forms
in South Africa, but as the epidemic evolves, more mixing
of clades can be expected, resulting in recombinant forms
of HIV-1. There are published reports suggesting that
cross-c1ade reactivity can be induced by natural infection,
but homologous responses are frequently greater than
heterologous responses.'~
Other ways of addressing diversity issues can include
multivalent cocktails of proteins that comprise a spectrum
of regional variants with the assumption that the immune
responses elicited by anyone of the circulating strain will
be of sufficient cross-reactivity to protect against other
strains from the same subtype.'
ADOLESCENT INVOLVEMENT
One of the most effective ways to curb the epidemic will be
to vaccinate older children and adolescents prior to their
sexual debut, particularly in South Africa where 50% of 15-
year-aids and almost 10% of under-12-year-olds are
sexually experienced. The use of an HIV vaccine in this
population will require clinical trials in adolescents to
determine the vaccine's safety and immunogenicity as the
Food and Drug Administration (FOAl and international
licensing agencies will probably only license the vaccine for
use in age groups in which it has been tested. Generally,
candidate HIV vaccines have been studied in phase 1/11 trials
in healthy adult volunteers. To date, no HIV vaccines have
been evaluated in adolescents.
There are challenges researchers need to overcome to
successfully complete HIV vaccine trials in adolescents, and
because of this, adolescents are often excluded from
clinical research. Treatments and interventions used in this
group are usually extrapolated from studies performed in
children or adults.' Many national committees and panels
have recognised the lack of research involving adolescents,
and have urged that more research be conducted in this
age group.
South Africa needs a clear strategy to involve adolescents
in vaccine trials. Ethical issues regarding informed consent,
consultation with parents and HIV testing of minors need
to be addressed in an expedient manner.
ESTABUSHMENT OF HIV VACCINE CUNICAL SITES
Disparities exist between urban and rural health care and
'local standards of care' differ dramatically. In rural areas,
the doctor/patient ratio is lower than in urban areas, where
patients may only access rotating medical doctors at a
primary health care level once a week. Access to drugs on
the essential drug list may be sporadic, and there are
concerns that in rural areas where trial sites are being
developed, better access to medical care may act as a
perverse incentive for clinical trial participation. In a survey
conducted in Soweto, an urban African setting on the
outskirts of Johannesburg, almost 70% of participants
stated that they would definitely participate in HIV vaccine
research. Access to HIV testing, risk reduction counselling
and condoms, and treatment of sexually transmitted
diseases were cited as reasons to be involved in HIV vaccine
clinical trials. In this survey, only 36% of participants
believed that HAART should be provided to trial volunteers
who had breakthrough infections.
TRAINING OF RESEARCHERS
Clinical researchers need to be trained adequately so that
all trials conducted in South Africa are in accordance with
the International Conference on Harmonisation of Good
Clinical Practice (ICH GCP) and the highest ethical
standards. In South Africa there are currently few
researchers trained in ICH GCP and able to conduct trials
under Federal Drug Administration (FOAl scrutiny. In
addition, there are no concrete plans in South Africa to
develop sufficient phase III capability to allow the testing
of suitable vaccine candidates in phase III clinical trials.
There is a paucity of black African scientists involved in HIV
research, and in particular HIV vaccine research, in South
Africa. To this end, the academic institutions involved in
HIV vaccine research have committed themselves to the
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development of scientists from previously disadvantaged
communities and prioritised the training of both clinical
and laboratory scientists.
PROTECTING TRIAL PARTICIPANTS
South Africa is uncharted territory in terms of HN vaccine
clinical research. HIV vaccine trials to be conducted in
South Africa will largely involve people from populations
which, through limited knowledge about science and
research, advanced poverty, unemployment and gender
inequality, may be vulnerable to exploitation and
manipulation by research programmes. Trial participants
deserve protection from social harm or any form of
discrimination that may arise from their participation in
HIV vaccine research.
It is therefore apparent that South Africa needs to work on
legislation that will ensure the protection of trial
participants from any form of harm arising from
participating in HIV vaccine research. Some units within
South Africa have built up considerable skills, infrastructure
and approaches to HIV clinical trials. These will be
fundamental to designing and carrying out successful
vaccine trials in communities, which in the process will be
enabled to become research-literate and empowered
partners.
INVOLVING COMMUNmES
Public dialogue, education and outreach are essential for
successful HIV vaccine research and this process has not
been systematic in South Africa. There is a need to embrace
communities involved in research in a meaningful and
constructive way. One way of achieving this is by the
establishment of democratically elected and truly
respresentative community advisory boards (CABs). Regular
contact and communication between the CAB and
researchers will open up channels of dialogue necessary to
facilitate the successful execution of clinical trials.
VACCINE ACCESS
Strategies must be developed now to ensure that after
being licensed the HN vaccine is readily available to all
sectors of the population.
SUMMARY
Although many steps are necessary for the successful
implementation of HIV vaccine clinical research, most of
the infrastructure and expertise exists in this country. To
expedite the approval and initiation of the first phase 1/11
trials in South Africa, it is apparent that local regulatory
capacity necessary for research and licensure needs to be
developed as a matter of urgency. An important issue that
threatened the initiation of HN vaccine research pertained
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to 'standards of care', and what this constitutes in a
country with no provision of HAART in the public sector.
Although this has been resolved at a policy level, it is
apparent that clinical researchers, together with local
institutional review boards and the national Department of
Health, will need to develop amodel of care for participants
who acquire 'breakthrough' infections while participating
in vaccine trials. This model will need to encompass the
challenges of long-term follow-up, monitoring and care,
including expertise in treating with HAART and ensuring an
uninterrupted supply of antiretroviral drugs. The national
Department of Health will need to take the lead in
establishing the national guidelines on 'standards of care'
and to provide the infrastructure and treatment necessary
for long-term follow-up and care for trial participants who
seroconvert on trials. SAAVI must continue to identify and
develop phase III clinical trial sites both in rural and urban
areas, preferably as soon as the phase 1/11 trials commence.
As the appropriate target group for vaccination will be
adolescents before their sexual debut, a strategy for
testing of HN vaccines in adolescents needs to be fast-
tracked in the region. Finally, once an efficacious vaccine
has been tested, a plan for the urgent procurement and
distribution is needed to make this vaccine available to all
South Africans as quickly as possible.
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